Moderna (MRNA.US) rises 20% in pre-market trading as the company and Merck announce that their melanoma skin cancer vaccine has achieved its primary goal in a large-scale trial.
智通财经2026/08/19 11:01Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
Moderna (MRNA.US) rose 20% in pre-market trading after the company and Merck announced that their melanoma skin cancer vaccine reached its target impact in a large-scale trial.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
